• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: a small molecule dual inhibitor of the enzymes LDHA and LDHB. LDH catalyzes the last committed step in the synthesis of oxalate.
Date Designated: 08/21/2024
Orphan Designation: treatment of primary hyperoxaluria
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Meta Pharmaceuticals (HK) Ltd
Unit 505, 5/F, Biotech Centre 1
No. 9 Science Park West Avenue, Hong Kong Science Park
Hong Kong, Special Administrative Region 999077
Hong Kong

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-